歡迎蒞臨南京沃博生物科技有限公司官方網(wǎng)站!

Cabozantinib (XL184,BMS 907351,Cometriq?) 卡博替尼

貨號 ICG1092 售價(元) 1918
規(guī)格 5mg CAS號 849217-68-1
  • 產(chǎn)品簡介
  • 相關產(chǎn)品

貨號

名稱

規(guī)格

價格

ICG1092-0005MG

Cabozantinib

5MG

1918

ICG1092-0010MG

Cabozantinib

10MG

3002

ICG1092-0050MG

Cabozantinib

50MG

8412

ICG1092-0100MG

Cabozantinib

100MG

16500

產(chǎn)品簡介:

       Cabozantinib (XL184,BMS-907351) 是一種新型 MET 和 VEGFR2 抑制劑,可同時抑制轉移、血管生成和腫瘤生長[1]。其對 VEGFR2 和 c-Met 的 IC50 值分別為 0.035 nM 和 1.3 nM[2]。

Cabozantinib(XL184) 處理 MDA-MB-231 和 HCC70 細胞的 MAME 培養(yǎng)物(表達 HGF 的成纖維細胞)具有細胞毒性并顯著減少多細胞侵襲性生長,即使在含有表達 HGF 的成纖維細胞的培養(yǎng)物中也是如此[3]。 Cabozantinib 誘導的細胞應激導致 DU-145 細胞系發(fā)生 ICD(一種特殊類型的細胞凋亡)[4]。據(jù)報道,卡博替尼可通過阻斷膀胱癌細胞中的 HGF-MET 信號通路來抑制 MMP-1 的表達[5]??ú┨婺崽幚砗驟SCC細胞MMP-1顯著降低,這是卡博替尼處理后ESCC細胞遷移活性降低的原因[6]。

卡博替尼抑制腫瘤生長在嚙齒動物的人類腫瘤模型中呈劑量依賴性[1]。體內(nèi)藥效學研究表明,單次口服卡博替尼[7]后,TT 異種移植腫瘤中的 RET 得到顯著抑制。使用 CRC(結直腸癌)外植體模型,卡博替尼在體內(nèi)表現(xiàn)出優(yōu)異的抗腫瘤作用[8]。

產(chǎn)品性質(zhì):

Cas No.:849217-68-1

別名:卡博替尼; XL184; BMS-907351

化學名: 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

Canonical SMILES COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F

分子式:C28H24FN3O5

分子量:501.51

溶解度:≥ 25.1mg/mL in DMSO

儲存條件:4°C, protect from light

注意事項:

為了您的安全和健康,請穿實驗服并戴一次性手套操作。

References:

[1]. Yakes F Michael,Chen Jason, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.[J]. Molecular cancer therapeutics,2011,10(12).

[2]. Weon-Kyoo You, Barbara Sennino, et al. VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer[J]. Microenvironment and Immunology,2011.

[3]. Sameni Mansoureh,Tovar Elizabeth A, et al. Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.[J]. Clinical cancer research : an official journal of the American Association for Cancer Research,2016,22(4).

[4] Scirocchi Fabio,Napoletano Chiara,et al. Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib[J]. Frontiers in Oncology,2021,11.

[5] Shintani T, Kusuhara Y, et al. The involvement of hepatocyte growth factor-MET-matrix metalloproteinase 1 signaling in bladder cancer invasiveness and proliferation. Effect of the MET inhibitor, cabozantinib (XL184), on bladder cancer cells. Urology. (2017) 101:169.e7-13. doi: 10.1016/j.urology.2016.12.006.

[6] Pei-Wen Yang, Yu-Cheng Liu, et al. Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)[J]. Frontiers in Oncology, 2019.

[7] Bentzien Frauke,Zuzow Marcus, et al. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.[J]. Thyroid : official journal of the American Thyroid Association,2013,23(12).

[8] Scott Aaron J,Arcaroli John J,et al. Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms.[J]. Molecular cancer therapeutics,2018,17(10).